Eflornithine Hydrochloride Hydrate

依氟鸟氨酸盐酸盐水合物

Report date: 2026/05/09 20:00:18

Base Information

Drug NameEflornithine Hydrochloride Hydrate
Drug Alias Nameeflornitina依氟鸟氨酸eflornithinumDifluoromethylornithineDFMO +[19] 
ClassificationSmall molecules > Amino acid supplement, Lipids and Vitamins
Mechanisms of ActionOrnithine decarboxylase inhibitors
TargetsOrnithine decarboxylase
Therapy Area/IndicationsGastric intestinal metaplasiaDiabetes Mellitus, Type 1Hirsutism +[12] 
Global Approved IndicationsHirsutism
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1990/11/28
Country/TerritoryMainland China(BOAO LECHENG)BelgiumCanada +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCancer Prevention Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNorgineCancer Prevention Pharmaceuticals IncOrbus Therapeutics Inc +[7] 
Inactive CompaniesNational Cancer InstituteUniversity Of Wisconsin-MadisonThe University Of Texas MD Anderson Cancer Center +[5] 
Active IndicationsGastric intestinal metaplasiaDiabetes Mellitus, Type 1Hirsutism +[6] 
Inactive IndicationsPrecancerous ConditionsUrinary Bladder NeoplasmsProstatic Neoplasms +[6] 

Other Information

ATC CodeD11AX16P01CX03
Related LinksWikipediaDrugBankKEGG